GLP-1s recently produced some of the most striking cancer findings:
- 30% lower breast cancer incidence
- 65% lower all-cause mortality in obese patients
- 91% lower mortality in diabetic patients vs insulin
- 31–50% cut in metastatic progression across 7 cancers
Pretty amazing for drugs that were initially developed to manage type 2 diabetes.
Women taking GLP-1 drugs (Ozempic, Wegovy, Mounjaro) were about 30% less likely to develop breast cancer, despite matching for age, BMI, race, diabetes status, & breast density.
The more we learn about this drug class, the more it looks like we've stumbled onto something big.
Your favorite peptide companies 30% off discount is still more expensive than our products without a discount. Let that sink in.
No, they are not potentially losing money for the greater good for you guys and gals.